Nitriles

Incyte Announces REACH3 Trial of Ruxolitinib (Jakafi®) in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoints

Retrieved on: 
Thursday, July 23, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Chemical compounds, Health, Medical specialties, Cyclopentanes, Nitriles, Pyrazoles, Ruxolitinib, Graft-versus-host disease, Novartis, Clinical endpoint, Incyte, REACH3, REACH, Jakafi® (ruxolitinib), Incyte

In addition, the study also met both key secondary endpoints, significantly improving failure-free survival (FFS) and patient-reported symptoms assessed by the modified Lee chronic GVHD symptom scale (mLSS).

Key Points: 
  • In addition, the study also met both key secondary endpoints, significantly improving failure-free survival (FFS) and patient-reported symptoms assessed by the modified Lee chronic GVHD symptom scale (mLSS).
  • The primary endpoint was overall response rate (ORR) at Day 1 of the Cycle 7 (Day 168) visit, defined as the percentage of participants demonstrating a complete or partial response.
  • The REACH clinical trial program evaluating ruxolitinib in patients with steroid-refractory GVHD includes the randomized pivotal Phase 3 REACH2 and REACH3 trials, conducted in collaboration with Novartis.
  • Jakafi is marketed by Incyte in the United States and by Novartis as Jakavi (ruxolitinib) outside the United States.

Global Acetonitrile Market Outlook, 2027: COVID-19 Revised Forecasting - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 21, 2020
Chemicals, Plastics, Manufacturing, Acetonitrile, Ligands, Nitriles, Solvents

The "Acetonitrile - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acetonitrile - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Acetonitrile estimated at US$232 Million in the year 2020, is projected to reach a revised size of US$290.8 Million by 2027, growing at a CAGR of 3.3% over the period 2020-2027.
  • This segment currently accounts for a 39.6% share of the global Acetonitrile market.
  • The country currently accounts for a 27% share in the global market.

Remdesivir Global Market Report 2020-30: COVID 19 Growth and Change

Retrieved on: 
Monday, July 20, 2020
Organic compounds, Health, Antivirals, Chemistry, COVID-19, Nitriles, Nucleotides, Remdesivir, Coronavirus disease, COVID-19 drug repurposing research, COVID-19 drug development

The remdesivir market consists of sales of remdesivir drugs currently found effective in treating the COVID-19 disease.

Key Points: 
  • The remdesivir market consists of sales of remdesivir drugs currently found effective in treating the COVID-19 disease.
  • The remdesivir market covered in this report is segmented by route of administration into oral; intravenous.
  • Increasing prevalence of COVID-19 disease globally is a key factor driving the growth of the remdesivir market.
  • Therefore, the increasing prevalence of COVID-19 disease across different parts of the globe is expected to drive the growth of the remdesivir market.

Bayer’s Finerenone Meets Primary Endpoint in Phase III FIDELIO-DKD Renal Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes

Retrieved on: 
Thursday, July 9, 2020
Science, Other Science, Research, Oncology, General Health, Health, Infectious diseases, Clinical trials, RTT, Organ failure, Medical specialties, Kidney diseases, Branches of biology, Finerenone, Naphthyridines, Nitriles, Medicine, Chronic kidney disease, Placebo-controlled study, Kidney failure, Finerenone, Chronic Kidney Disease in Type 2 Diabetes, Cardiology at Bayer, Bayer

Bayer today announced the Phase III study FIDELIO-DKD, which is evaluating the efficacy and safety of finerenone versus placebo when added to standard of care for chronic kidney disease (CKD) in patients with type 2 diabetes (T2D), has met its primary endpoint.

Key Points: 
  • Bayer today announced the Phase III study FIDELIO-DKD, which is evaluating the efficacy and safety of finerenone versus placebo when added to standard of care for chronic kidney disease (CKD) in patients with type 2 diabetes (T2D), has met its primary endpoint.
  • FIDELIO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study investigating finerenone versus placebo in patients with CKD and T2D.
  • There has been a recent uptick of both federal initiatives and public-private partnerships encouraging innovation to improve kidney health in America.
  • FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) investigated the efficacy and safety of finerenone in comparison to placebo in addition to standard of care on the reduction of kidney failure and kidney disease progression in approximately 5,700 patients with CKD and T2D.

European Commission Grants Conditional Marketing Authorization for Gilead’s Veklury® (remdesivir) for the Treatment of COVID-19

Retrieved on: 
Friday, July 3, 2020
Health, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Medicine, Articles, Health, Antivirals, Zoonoses, Nitriles, Nucleotides, Organophosphates, Remdesivir, Severe acute respiratory syndrome-related coronavirus, Gilead Sciences, Severe acute respiratory syndrome

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted conditional marketing authorization for Veklury (remdesivir) as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted conditional marketing authorization for Veklury (remdesivir) as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19.
  • This conditional marketing authorization is an important step forward as we work together to address the treatment needs of patients across Europe.
  • The conditional marketing authorization for Veklury is supported by the U.S. National Institute of Allergy and Infectious Diseases global Phase 3 trial of remdesivir.
  • A conditional marketing authorization in Europe is initially valid for one year but can be extended or converted into an unconditional marketing authorization after the submission and assessment of additional confirmatory data.

New Study Demonstrates GeneSight Psychotropic Better Predicts Blood Drug Levels When Compared to Single-Gene Testing

Retrieved on: 
Monday, June 8, 2020
Selective serotonin reuptake inhibitors, Branches of biology, Chemical compounds, RTT, Chemistry, Escitalopram, Nitriles, Citalopram, Medical genetics, Pharmacogenomics, Genetic testing

The study demonstrated the GeneSight Psychotropic test is better at predicting citalopram and escitalopram blood concentrations when compared to single-gene testing.

Key Points: 
  • The study demonstrated the GeneSight Psychotropic test is better at predicting citalopram and escitalopram blood concentrations when compared to single-gene testing.
  • The GeneSight test assesses and weighs multiple gene factors, which more accurately predicts blood drug levels and identifies more patients with significant gene-drug interactions who would be missed by single-gene testing, said Michael R. Jablonski, Ph.D., vice president of medical affairs, Myriad Neuroscience.
  • The study provides further evidence to support the superiority of GeneSights combinatorial testing relative to single-gene methodologies and guideline recommendations.
  • Furthermore, combinatorial pharmacogenomic testing explained more variance in citalopram blood levels when compared to single-gene testing.

The Global Acetonitrile Market is expected to grow by 34.57 th tons during 2020-2024 progressing at a CAGR of 6% during the forecast period

Retrieved on: 
Tuesday, June 2, 2020
Chemistry, Physical sciences, Natural sciences, Acetonitrile, Ligands, Nitriles, Solvents, Chromatography, High-performance liquid chromatography, Compound annual growth rate

The analyst has been monitoring the acetonitrile market and it is poised to grow by 34.57 th tons during 2020-2024 progressing at a CAGR of 6% during the forecast period.

Key Points: 
  • The analyst has been monitoring the acetonitrile market and it is poised to grow by 34.57 th tons during 2020-2024 progressing at a CAGR of 6% during the forecast period.
  • Our reports on acetonitrile market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The market is driven by the high consumption of acetonitrile in the pharmaceutical industry and high volume consumption of acetonitrile in HPLC.
  • In addition, high consumption of acetonitrile in the pharmaceutical industry is anticipated to boost the growth of the market as well.

Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

Retrieved on: 
Monday, June 1, 2020
Health, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Medicine, Medical specialties, Health, Specialty drugs, Gilead Sciences, Nitriles, Remdesivir, Mechanical ventilation, Gilead

An expansion phase of the study was added to enroll up to 5,600 additional patients, including those on mechanical ventilation.

Key Points: 
  • An expansion phase of the study was added to enroll up to 5,600 additional patients, including those on mechanical ventilation.
  • An expansion phase of the study was added to enroll up to 1,000 additional patients with moderate disease.
  • The initial study results are announced in this press release, and results from the expansion phase are expected in the coming months.
  • GS-5734, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc. or its related companies.

Sierra Oncology Announces Presentations at Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 27, 2020
Nitriles, Morpholines, Myelofibrosis, Janus kinase inhibitor, Momelotinib, Cancer, Forward-looking statement, Clinical medicine, Chemistry

More than 1,200 subjects have received momelotinib since clinical studies began in 2009, including more than 820 patients treated for myelofibrosis.

Key Points: 
  • More than 1,200 subjects have received momelotinib since clinical studies began in 2009, including more than 820 patients treated for myelofibrosis.
  • Sierra has launched MOMENTUM, a randomized double-blind Phase 3 clinical trial designed to enroll 180 myelofibrosis patients who are symptomatic and anemic, and who have been treated previously with a JAK inhibitor.
  • All statements other than statements of historical fact are statements that could be deemed forward-looking statements.
  • Sierra Oncology undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Sermo reports: Worldwide Remdesivir usage grows, but 67% of doctors believe Remdesivir would be most effective administered earlier, before patients become severely ill

Retrieved on: 
Thursday, May 21, 2020
Research, Infectious diseases, Public policy, Government, Healthcare reform, State, Local, General Health, Pharmaceutical, Health, Public policy, Science, Organic compounds, Health, Chemical compounds, RTT, Antivirals, Nitriles, Nucleotides, Organophosphates, Remdesivir, Hydroxychloroquine, Clinical trial, the Real Time Barometer, Sermo

View the full release here: https://www.businesswire.com/news/home/20200521005200/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200521005200/en/
    *Results provide physician observations, but are not a substitute for official medical guidelines or clinical trials.
  • The Earlier the Better with Remdesivir, but this Contradicts Official Indication
    The current official indication for Remdesivir is for severe COVID-19.
  • However, two-thirds (67%) of physicians believe Remdesivir is best administered earlier, for all moderate patients in the hospital before their symptoms become severe.
  • Our data shows that physicians perceive both Hydroxychloroquine and Remdesivir to be more effective earlier in the disease progression.